NYSE:ZBH
ZIMMER BIOMET HOLDINGS, INC.
A global leader in orthopedic medical technology delivering innovative joint replacement and spine solutions with robust cash flow and market dominance.
Key Metrics
Investment Thesis
Bull Case
ZBH offers exposure to the aging demographic driving demand for orthopedic procedures globally, supported by its premium brand positioning in hip and spine markets. The company's robust free cash flow generation allows for consistent share repurchases of $487M and dividend payments, enhancing shareholder returns without relying on external financing. Its diversified geographic footprint and large installed base of implants create recurring revenue streams and high switching costs for customers.
Bear Case
Recent net income contraction to $705.1M from $905.3M in 2024 signals potential margin pressure or one-time charges that could persist if competitive dynamics worsen. Significant accumulated other comprehensive loss of -$205.7M and a retained earnings deficit of -$11.6B suggest historical volatility in earnings quality or substantial prior losses impacting equity. Heavy reliance on capital expenditures of $224.5M and investing cash outflows of nearly $2B indicates ongoing heavy asset investment that may not yet translate to proportional revenue growth.
About ZIMMER BIOMET HOLDINGS, INC.
Zimmer Biomet Holdings (ZBH) is a leading orthopedic medical technology company specializing in joint replacement and spine products. Serving hospitals, surgical centers, and distributors globally, the company provides innovative implants and instruments for hip, knee, shoulder, and spine surgeries. With over $8.2B in 2025 revenue and strong cash flow generation, ZBH remains a dominant player in the high-margin orthopedic market.
Analysis
Management Discussion
ZBH reported $830.8M in profit before tax and $705.1M in net income for 2025, though this represents a decline from the $905.3M recorded in 2024. Operating cash flow of $1.7B significantly exceeds net income due to non-cash adjustments totaling over $1B including depreciation and amortization. Despite a substantial drop in revenue growth compared to prior years, the company maintains strong liquidity with ending cash matching beginning cash plus operations.
Industry Overview
The orthopedic implant industry is characterized by high barriers to entry due to rigorous FDA regulatory requirements, long product development cycles, and specialized surgical training needs. Market consolidation continues as larger players acquire smaller innovators to gain scale and technology portfolios, though price competition remains fierce in knee replacement segments. Growth is driven by demographic shifts toward an aging population and advancements in minimally invasive surgical techniques.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $6.94B | $7.39B | $7.68B | $8.23B |
| Cost of Revenue | $2.02B | $2.08B | $2.19B | $2.49B |
| Gross Profit | $4.92B | $5.31B | $5.49B | $5.74B |
| Operating Expenses | $4.22B | $4.03B | $4.20B | $4.64B |
| Operating Income | $696.3M | $1.28B | $1.29B | $1.10B |
| G&A | $2.76B | $2.84B | $2.93B | $3.26B |
| Stock-Based Comp | $105.0M | $99.8M | $101.0M | $90.2M |
| D&A | $926.4M | $951.7M | $996.3M | $1.09B |
| Depreciation | $399.6M | $390.2M | $404.4M | $427.9M |
| Amortization | $526.8M | $561.5M | $591.9M | $665.9M |
| Other OpEx | $1.46B | $1.19B | $1.27B | $1.38B |
| Non-Operating Income | $-292.8M | $-210.4M | $-249.1M | $-267.3M |
| Pre-Tax Income | $403.5M | $1.07B | $1.04B | $830.8M |
| Income Tax | $112.3M | $42.2M | $131.4M | $125.7M |
| Continuing Ops | $291.2M | $1.03B | $905.2M | $705.1M |
| Discontinued Ops | $-58.8M | $0 | $0 | $0 |
| Net Income | $232.4M | $1.03B | $905.3M | $705.1M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $232.4M | $1.03B | $905.3M | $705.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $4.43B | $4.61B | $4.67B | $5.12B |
| Cash & Equivalents | $375.7M | $415.8M | $525.5M | $591.9M |
| Accounts Receivable | $1.38B | $1.44B | $1.48B | $1.70B |
| Inventory | $2.15B | $2.39B | $2.24B | $2.29B |
| Prepaid Expenses | $324.5M | $366.1M | $430.1M | $537.3M |
| Other Current Assets | $198.4M | $0 | $-100.0K | $-100.0K |
| Long-Term Assets | $16.64B | $16.89B | $16.69B | $17.97B |
| PP&E (Net) | $1.87B | $2.06B | $2.05B | $2.21B |
| Intangibles | $5.06B | $4.86B | $4.60B | $4.72B |
| Goodwill | $8.58B | $8.82B | $8.95B | $9.95B |
| Operating Leases | $196.4M | $203.8M | $213.5M | $204.2M |
| Other LT Assets | $925.8M | $948.3M | $882.0M | $896.1M |
| Total Assets | $21.07B | $21.50B | $21.37B | $23.09B |
| Current Liabilities | $2.36B | $2.86B | $2.45B | $2.58B |
| Accounts Payable | $354.1M | $410.6M | $194.6M | $303.0M |
| Current Debt | $544.3M | $900.0M | $863.0M | $587.1M |
| Current Leases | $53.0M | $52.9M | $53.2M | $57.5M |
| Taxes Payable | $38.5M | $61.2M | — | — |
| Other Current Liab | $786.0M | $805.0M | $606.0M | $801.6M |
| Long-Term Liabilities | $6.68B | $6.15B | $6.44B | $7.80B |
| Long-Term Debt | $5.15B | $4.87B | $5.34B | $6.93B |
| LT Operating Leases | $167.3M | $174.4M | $190.2M | $175.5M |
| Other LT Liab | $940.1M | $835.3M | $906.4M | $694.8M |
| Total Liabilities | $9.04B | $9.01B | $8.89B | $10.39B |
| Shareholders' Equity | $12.03B | $12.49B | $12.48B | $12.71B |
| Retained Earnings | $9.56B | $10.38B | $11.10B | $11.61B |
| AOCI | $-179.3M | $-191.0M | $-262.8M | $-205.7M |
| Treasury Stock | $6.87B | $7.56B | $8.41B | $8.89B |
| Total L&E | $21.07B | $21.50B | $21.37B | $23.09B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $232.4M | $1.03B | $905.3M | $705.1M |
| Non-Cash Adjustments | $840.7M | $418.5M | $1.10B | $1.02B |
| Working Capital Changes | $211.6M | $138.0M | $-505.8M | $-24.7M |
| Cash from Operations | $1.28B | $1.58B | $1.50B | $1.70B |
| Capital Expenditures | $187.9M | $291.1M | $203.8M | $224.5M |
| Cash from Investing | $-529.2M | $-778.9M | $-888.1M | $-1.98B |
| Share Buybacks | $126.4M | $692.2M | $868.0M | $487.0M |
| Dividends Paid | $201.2M | $200.9M | $196.0M | $190.3M |
| Cash from Financing | $-843.8M | $-763.5M | $-484.5M | $326.0M |
| FX Effect | $-14.5M | $900.0K | $-17.1M | $19.0M |
| Net Change in Cash | $-102.8M | $40.1M | $109.7M | $66.4M |
| Beginning Cash | $478.5M | $375.7M | $415.8M | $525.5M |
| Ending Cash | $375.7M | $415.8M | $525.5M | $591.9M |
Frequently Asked Questions
How does ZIMMER BIOMET HOLDINGS, INC. make money?
The company generates revenue primarily through its Orthopaedics segment, which includes hip, knee, shoulder, and hand products; the Spine segment focusing on spinal implants and instrumentation; and its Medical Devices division offering surgical tools and accessories. Additionally, contract manufacturing services contribute to total operating expenses and revenue structure.
What are the main risks for ZBH?
Regulatory risks from the FDA and international health authorities regarding implant safety and post-market surveillance could impact product approvals or sales. Intense price competition from generic manufacturers and biosimilar entrants may compress margins over time, especially in knee replacement where ZBH has faced significant pricing pressure. Foreign exchange volatility impacts global revenue recognition given the company's international operations, as evidenced by FX effects on cash flow. Patent expirations on key implants could lead to market share erosion if follow-on products are not timely developed.
What is ZBH's competitive advantage?
ZBH holds a massive goodwill base of nearly $10B reflecting its portfolio of acquired technologies and established market share in high-barrier-to-entry orthopedic markets. The company benefits from a diversified product mix across multiple joint replacement categories, reducing reliance on any single procedure type. Strong balance sheet with $592M in cash allows for continued R&D investment and strategic M&A activity to expand its technology portfolio.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.